See analyst estimates and all valuation multiples for Vaccines & Immunotherapies
| Company | EV | EV/LTM Revenue | EV/LTM EBITDA |
|---|---|---|---|
| $229B | 3.5x | 8.2x | |
| $187B | 3.0x | 7.7x | |
| $134B | 2.5x | 8.4x | |
| $96.6B | 2.2x | 6.5x | |
| $89.1B | 5.6x | 17.0x | |
| $39.5B | 5.2x | 19.0x | |
| $10.2B | 3.8x | -7.0x | |
| $10.1B | n/a | n/a | |
| $8.2B | 2.6x | 21.3x | |
| $6.6B | 7.1x | 25.6x | |
| $6.3B | 2.4x | -1.7x | |
| $6.2B | 13.8x | 43.7x | |
| $5.4B | 14.3x | 85.0x | |
| $3.7B | 5.6x | 14.3x | |
| $2.9B | 50.2x | n/a | |
| $2.6B | 16.8x | -34.8x | |
| $2.6B | n/a | n/a | |
| $2.6B | 6.4x | 24.9x | |
| $2.5B | n/a | n/a | |
| $2.2B | 6.9x | -89.7x | |
| $2.0B | 5.1x | 22.6x | |
| $1.9B | 2.0x | 6.7x | |
| $1.5B | n/a | n/a | |
| $1.3B | n/a | n/a | |
| $1.2B | 6.7x | 23.7x | |
| $1.1B | 5.5x | 8.2x | |
| $1.1B | 5.9x | 22.6x | |
| $1.1B | 5.1x | 13.2x | |
| $862M | 2.8x | 25.3x | |
| $852M | 5.9x | 11.7x | |
| $850M | 15.3x | -67.2x | |
| $845M | 1374.7x | n/a | |
| $772M | 3.2x | 10.3x | |
| $769M | 4.0x | n/a | |
| $741M | 2.2x | 14.3x | |
| $723M | 138.1x | -3.3x | |
| $720M | 6.7x | 8.8x | |
| $630M | n/a | n/a | |
| $596M | 1.7x | 10.2x | |
| $568M | 0.7x | 4.8x | |
| $552M | 6.9x | -23.3x | |
| $551M | n/a | -9.4x | |
| $547M | 2.6x | -163.5x | |
| $506M | 368.7x | -24.6x | |
| $444M | 67.6x | -1.8x | |
| $439M | 1.9x | n/a | |
| $415M | n/a | n/a | |
| $407M | 18.1x | 93.8x | |
| $382M | 2.2x | 9.7x | |
| $365M | 4.3x | -3.3x | |
| $346M | 408105.2x | -14.5x | |
| $336M | 21.7x | -1.2x | |
| $302M | 2.6x | 19.7x | |
| $288M | 4.3x | -2.4x | |
| $277M | 85.1x | n/a | |
| $276M | 1.4x | 6.5x | |
| $274M | 1.7x | -2.6x | |
| $259M | 615.4x | n/a | |
| $258M | 642.1x | n/a | |
| $257M | n/a | n/a | |
| $233M | n/a | n/a | |
| $216M | n/a | n/a | |
| $216M | 1.9x | n/a | |
| $169M | n/a | -5.3x | |
| $161M | 81.2x | -1.4x | |
| $147M | 26.4x | -8.4x | |
| $143M | 4.2x | -0.7x | |
| $143M | n/a | n/a | |
| $138M | n/a | n/a | |
| $132M | n/a | n/a | |
| $126M | n/a | n/a | |
| $123M | n/a | n/a | |
| $118M | 1.6x | 3.6x | |
| $114M | n/a | n/a | |
| $113M | 5.5x | n/a | |
| $112M | n/a | n/a | |
| $104M | 4.5x | -5.0x | |
| $88.0M | n/a | n/a | |
| $77.9M | 0.6x | 9.9x | |
| $76.1M | 19731.9x | -3.3x | |
| $63.2M | n/a | n/a | |
| $62.6M | 14.7x | n/a | |
| $62.2M | n/a | n/a | |
| $61.0M | 2.7x | n/a | |
| $58.9M | n/a | -0.6x | |
| $58.2M | n/a | -2.7x | |
| $55.0M | 3684.0x | -0.2x | |
| $54.0M | 0.5x | -0.5x | |
| $53.0M | 0.5x | -0.6x | |
| $47.9M | 1.9x | n/a | |
| $46.7M | 5.4x | n/a | |
| $43.7M | 1181.5x | n/a | |
| $40.3M | n/a | n/a | |
| $37.2M | 0.5x | -0.4x | |
| $34.7M | n/a | -0.9x | |
| $34.6M | 396.4x | n/a | |
| $31.0M | 13.7x | -0.2x | |
| $29.8M | n/a | n/a | |
| $25.2M | 505.6x | -0.7x | |
| $23.5M | 3.8x | -1.2x | |
| $23.3M | 1.4x | n/a | |
| $22.9M | 0.5x | -0.0x | |
| $21.5M | 4.4x | n/a | |
| $12.1M | 15.3x | n/a | |
| $11.1M | 0.6x | n/a | |
| $10.0M | n/a | n/a | |
| $8.8M | n/a | n/a | |
| $6.6M | n/a | n/a | |
| $6.6M | 2.5x | n/a | |
| $5.7M | n/a | n/a | |
| -$0.4M | -0.1x | 0.0x | |
| -$2.9M | -0.5x | n/a | |
| -$7.9M | -10.7x | n/a | |
| -$8.3M | -51.5x | n/a | |
| -$20.7M | -7.5x | 0.3x | |
| -$20.8M | n/a | n/a | |
| -$25.3M | -0.6x | n/a | |
| -$26.9M | -4.4x | 0.2x | |
| -$30.9M | -0.2x | n/a | |
| -$32.8M | n/a | n/a | |
| -$35.6M | -4.1x | 0.2x | |
| -$38.6M | n/a | n/a | |
| -$43.6M | -8.6x | 1.0x | |
| -$45.0M | -2.8x | n/a | |
| -$49.8M | -6.9x | n/a | |
| -$58.1M | n/a | 0.6x | |
| -$64.1M | n/a | 0.7x | |
| -$66.6M | -0.4x | 0.2x | |
| -$66.7M | n/a | n/a | |
| -$69.4M | n/a | n/a | |
| -$72.6M | -14.0x | 0.6x | |
| -$80.5M | n/a | n/a | |
| -$113M | -937.6x | n/a | |
| -$117M | -3536.3x | 0.5x | |
| -$126M | n/a | 0.8x | |
| -$130M | -7.7x | 0.8x |
Valuation multiples as of last 12 months (LTM). Financial data powered by Morningstar, Inc.
See analyst estimates and M&A multiples for Vaccines & Immunotherapies